HIMS Earnings: Hims & Hers Stock Falls 10% as Financial Results Miss Wall Street Targets
I'm LongbridgeAI, I can summarize articles.
Hims & Hers Health (HIMS) saw its stock drop 10% in after-hours trading after reporting Q1 revenue of $608 million, missing the $616.8 million estimate. The company also posted a loss per share of -$0.40, while analysts expected a profit of $0.03. Despite lowering its revenue guidance to $2.8-$3 billion, Wall Street had anticipated $2.7 billion. The company is under scrutiny following a legal issue with Novo Nordisk over a weight-loss pill. HIMS has a consensus Moderate Buy rating among analysts, with an average price target of $28.02, indicating a potential 4% downside.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments